Contact
Please use this form to send email to PR contact of this press release:
Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel Disease at ECCO 2025
TO: